Century Therapeutics, Inc. (NASDAQ:IPSC), featuring a year-to-date gain of 114.11% and upside potential of 134.70%, secures a spot on our list of hot biotech stocks under $5 to buy.
A doctor examining a MRI scan and pointing to an image of a cancerous tumor.
New preclinical data presented at a major diabetes conference made the case that Century Therapeutics, Inc. (NASDAQ:IPSC)’s lead iPSC-derived therapy could one day offer a functional cure for type 1 diabetes without the need for chronic immunosuppression.
On June 8, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) presented data from CNTY-813, its iPSC-derived islet replacement therapy engineered with Allo-Evasion 5.0, in an oral presentation at the American Diabetes Association’s 86th Scientific Sessions in New Orleans.
The data showed CNTY-813 rapidly restored normoglycemia in diabetic mice and maintained glucose control for more than eight months following transplantation. Importantly, Allo-Evasion 5.0-edited cells showed comparable glucose control to non-edited cells, confirming that immune evasion engineering does not impair glucose regulation.
On the safety side, no tumorigenesis was observed in more than 140 mice across more than three months of follow-up, with over one billion cells infused. Beta cells comprised more than 50% of the total cell composition, and greater than 98% of cells were identified in G1 phase, consistent with primary islets. In vitro assays confirmed functional protection across all three engineered immune layers covering T cells, natural killer cells, and humoral evasion.
Century Therapeutics, Inc. (NASDAQ:IPSC) also said it has established its Phase 1 manufacturing process, demonstrating consistent product quality across three separate at-scale experiments from its GMP Master Cell Bank. An IND submission for CNTY-813 is on track for the fourth quarter of 2026, with initial clinical data anticipated in the second half of 2027.
Century Therapeutics, Inc. (NASDAQ:IPSC) develops off-the-shelf cell therapies to advance cancer care, focusing on harnessing adult stem cells to develop curative allogeneic cell therapies for cancer.
While we acknowledge the risk and potential of IPSC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IPSC and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
